The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®

被引：0
作者：
F. Borgström
O. Ström
J. Coelho
H. Johansson
A. Oden
E. V. McCloskey
J. A. Kanis
机构：
[1] Karolinska Institute,Medical Management Centre
[2] I3 Innovus,undefined
[3] Centre for Metabolic Bone Diseases (WHO Collaborating Centre) University of Sheffield Medical School,undefined
来源：
Osteoporosis International | 2010年 / 21卷
关键词：
Cost-effectiveness; Fractures; FRAX; Osteoporosis; QALY;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：495 / 505
页数：10
相关论文
共 50 条
  • [31] Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis
    Patrizia Berto
    Stefania Maggi
    Marianna Noale
    Stefania Lopatriello
    Aging Clinical and Experimental Research, 2010, 22 : 179 - 188
  • [32] Development and application of FRAX in the management of osteoporosis in Ireland
    McGowan, B.
    Kanis, John A.
    Johansson, H.
    Silke, C.
    Whelan, B.
    ARCHIVES OF OSTEOPOROSIS, 2013, 8 (1-2)
  • [33] Cost-effectiveness of physical activity in the management of COPD patients in the UK
    Ramos, Mafalda
    Lamotte, Mark
    Gerlier, Laetitia
    Svangren, Per
    Miquel-Cases, Anna
    Haughney, John
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019, 14 : 227 - 239
  • [34] Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment
    Penton, H.
    Hiligsmann, M.
    Harrison, M.
    Reginster, J. -Y.
    Boonen, A.
    Bansback, N.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 (09) : 2697 - 2707
  • [35] Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment
    H. Penton
    M. Hiligsmann
    M. Harrison
    J.-Y. Reginster
    A. Boonen
    N. Bansback
    Osteoporosis International, 2016, 27 : 2697 - 2707
  • [36] Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review
    Y. Wan
    F. Zeng
    H. Tan
    Y. Lu
    Y. Zhang
    L. Zhao
    R. You
    Osteoporosis International, 2022, 33 : 979 - 1015
  • [37] Cost-effectiveness strategies to treat osteoporosis in elderly women
    Pfister, Alfred K.
    Welch, Christine A.
    Lester, Melissa D.
    Emmett, Mary K.
    Saville, Paul D.
    Duerring, Shea A.
    SOUTHERN MEDICAL JOURNAL, 2006, 99 (02) : 123 - 131
  • [38] Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis
    Hiligsmann, Mickael
    Vanoverberghe, Marie
    Neuprez, Audrey
    Bruyere, Olivier
    Reginster, Jean-Yves
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2010, 10 (04) : 359 - 366
  • [39] Prevention of osteoporosis: Cost-effectiveness of different pharmaceutical treatments
    AnkjaerJensen, A
    Johnell, O
    OSTEOPOROSIS INTERNATIONAL, 1996, 6 (04) : 265 - 275
  • [40] Cost-Effectiveness of Osteoporosis Interventions for 'Incidental' Vertebral Fractures
    Majumdar, Sumit R.
    Lier, Douglas A.
    McAlister, Finlay A.
    Rowe, Brian H.
    Siminoski, Kerry
    Hanley, David A.
    Russell, Anthony S.
    Johnson, Jeffrey A.
    AMERICAN JOURNAL OF MEDICINE, 2013, 126 (02) : 169.e9 - 169.e17
12345